FDA
-
-
-
-
-
-
-
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
-
-
-
-
-
-
-
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
-
-
-
-
-
-
-
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
-
-
-
-
-
-
-
Trovagene (TROV) Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-mCRC
-
-
-
-
-
-
-
Trovagene (TROV) Reports Complete Phase 1b Trial of Onvansertib in AML; Commences Patient Enrollment in Phase 2
-
-
-
-
-
-
-
Trovagene (TROV) Commences Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer
-
-
-
-
-
-
-
Trovagene Announces First Quarter 2019 Results and Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

